Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PACS Stock Forecast 2026-2027
$35.20
Current Price
$5.53B
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PACS Price Targets
+47.7%
To High Target of $52.00
+25.0%
To Median Target of $44.00
+19.3%
To Low Target of $42.00
PACS Price Momentum
+3.9%
1 Week Change
+5.3%
1 Month Change
+280.1%
1 Year Change
-8.3%
Year-to-Date Change
-18.3%
From 52W High of $43.08
+369.3%
From 52W Low of $7.50
📊 TOP ANALYST CALLS
Did PACS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if PACS Group is one of their latest high-conviction picks.
Latest PACS Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, PACS has a bullish consensus with a median price target of $44.00 (ranging from $42.00 to $52.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $35.20, the median forecast implies a 25.0% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ben Hendrix at RBC Capital, projecting a 47.7% upside. Conversely, the most conservative target is provided by Michael Wiederhorn at Oppenheimer, suggesting a 19.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PACS Analyst Ratings
6
Buy
0
Hold
0
Sell
PACS Price Target Range
Low
$42.00
Average
$44.00
High
$52.00
Current: $35.20
Latest PACS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PACS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 4, 2026 | Oppenheimer | Michael Wiederhorn | Outperform | Maintains | $42.00 |
| Mar 4, 2026 | UBS | A.J. Rice | Buy | Maintains | $44.00 |
| Feb 27, 2026 | RBC Capital | Ben Hendrix | Outperform | Maintains | $52.00 |
| Dec 18, 2025 | UBS | A.J. Rice | Buy | Reinstates | $42.00 |
| Dec 17, 2025 | JP Morgan | Benjamin Rossi | Overweight | Reinstates | $44.00 |
| Nov 20, 2025 | RBC Capital | Ben Hendrix | Outperform | Maintains | $33.00 |
| Jan 6, 2025 | Macquarie | Tao Qiu | Outperform | Maintains | $24.00 |
| Jan 6, 2025 | Truist Securities | David Macdonald | Buy | Maintains | $32.00 |
| Dec 17, 2024 | JP Morgan | Neutral | Downgrade | $N/A | |
| Nov 18, 2024 | Stephens & Co. | Scott Fidel | Overweight | Maintains | $31.00 |
| Nov 6, 2024 | JP Morgan | Lisa Gill | Overweight | Reinstates | $40.00 |
| Oct 14, 2024 | Truist Securities | David Macdonald | Buy | Maintains | $46.00 |
| Oct 9, 2024 | UBS | A.J. Rice | Buy | Initiates | $50.00 |
| Sep 11, 2024 | Citigroup | Jason Cassorla | Buy | Reinstates | $45.00 |
| Aug 15, 2024 | Truist Securities | David Macdonald | Buy | Maintains | $44.00 |
| Aug 13, 2024 | Oppenheimer | Michael Wiederhorn | Outperform | Maintains | $40.00 |
| Aug 13, 2024 | Stephens & Co. | Scott Fidel | Overweight | Maintains | $40.00 |
| Aug 13, 2024 | Citigroup | Jason Cassorla | Buy | Maintains | $41.00 |
| Jul 15, 2024 | Truist Securities | David Macdonald | Buy | Maintains | $36.00 |
| Jun 28, 2024 | Macquarie | Tao Qiu | Outperform | Initiates | $35.00 |
Pacs Group Inc. (PACS) Competitors
The following stocks are similar to PACS Group based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Pacs Group Inc. (PACS) Financial Data
Pacs Group Inc. has a market capitalization of $5.53B with a P/E ratio of 28.9x. The company generates $5.29B in trailing twelve-month revenue with a 3.6% profit margin.
Revenue growth is +12.4% quarter-over-quarter, while maintaining an operating margin of +7.0% and return on equity of +23.0%.
Valuation Metrics
Market Cap
$5.53B
Enterprise Value
$8.94B
P/E Ratio
28.9x
PEG Ratio
14.9x
Price/Sales
1.0x
Growth & Margins
Revenue Growth (YoY)
+12.4%
Gross Margin
+16.5%
Operating Margin
+7.0%
Net Margin
+3.6%
EPS Growth
+60.5%
Financial Health
Cash/Price Ratio
+3.6%
Current Ratio
1.1x
Debt/Equity
377.8x
ROE
+23.0%
ROA
+3.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Pacs Group Inc. (PACS) Business Model
About Pacs Group Inc.
What They Do
Operates a national platform of post-acute care facilities.
Business Model
PACS Group Inc. generates revenue by managing a diverse portfolio of over 300 independently operated healthcare facilities that provide skilled nursing, assisted living, and independent living services. The company enhances its income through offering comprehensive support services, including technology solutions and training programs, to its affiliated providers, thereby creating a robust ecosystem that ensures consistent care and operational efficiency.
Additional Information
Founded in 2013 and headquartered in Salt Lake City, Utah, PACS operates in 17 states and serves tens of thousands of patients daily. Its entrepreneurial model allows for a balance between centralized resources and local operational autonomy, positioning it as a key player in the post-acute care sector.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
47,455
CEO
Mr. Jason Murray
Country
United States
IPO Year
N/A
Website
pacs.comPacs Group Inc. (PACS) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Wall Street Analysts Believe PACS Group, Inc. (PACS) Could Rally 31.15%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 31.2% in PACS Group, Inc. (PACS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Apr 09, 2026
By Zacks Equity Research
Tale of the Tape
PACS vs. MEDP: Which Stock Is the Better Value Option?
PACS vs. MEDP: Which Stock Is the Better Value Option?
Apr 08, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
New Strong Buy Stocks for April 14th
6 days ago
Quick Summary
SHEL, XYZ, UAA, PACS, and LAUR have been upgraded to Zacks Rank #1 (Strong Buy) as of April 14, 2026.
Why It Matters
Stocks added to the Zacks Rank #1 list indicate strong buy potential, suggesting positive earnings momentum and favorable outlooks, which may attract investor interest and drive stock prices higher.
Source: Zacks Investment Research
Market Sentiment:
Positive
Wall Street Analysts Believe PACS Group, Inc. (PACS) Could Rally 31.15%: Here's is How to Trade
11 days ago
Quick Summary
Wall Street analysts project a 31.2% upside for PACS Group, Inc. (PACS), supported by a positive trend in earnings estimate revisions.
Why It Matters
A 31.2% potential upside in PACS Group's price targets, coupled with positive earnings estimate revisions, suggests strong growth prospects, influencing investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors in the Medical Services sector are considering PACS Group, Inc. (PACS) and Medpace (MEDP) as potential undervalued stock options.
Why It Matters
The comparison of PACS Group, Inc. and Medpace highlights potential undervalued stocks in the Medical Services sector, influencing investment decisions and portfolio strategies.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors in Medical Services stocks are evaluating PACS Group, Inc. (PACS) and Medpace (MEDP) to determine which stock offers better value.
Why It Matters
The comparison of PACS Group and Medpace highlights potential investment opportunities in Medical Services, signaling where value investors might find better returns.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
PACS Group, Inc. (NYSE: PACS) will present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 17, 2026, featuring CEO Jason Murray and CFO Mark Hancock.
Why It Matters
PACS Group's participation in a major healthcare conference highlights its visibility and potential growth in the post-acute healthcare sector, which could influence investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
BTSG, INNV, and PACS may gain from the medical services industry's shift towards digital health and analytics, despite ongoing workforce shortages affecting providers.
Why It Matters
BTSG, INNV, and PACS may see growth as digital health adoption rises, but workforce shortages could limit the overall market potential and impact service delivery.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Frequently Asked Questions About PACS Stock
What is Pacs Group Inc.'s (PACS) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, Pacs Group Inc. (PACS) has a median price target of $44.00. The highest price target is $52.00 and the lowest is $42.00.
Is PACS stock a good investment in 2026?
According to current analyst ratings, PACS has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $35.20. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PACS stock?
Wall Street analysts predict PACS stock could reach $44.00 in the next 12 months. This represents a 25.0% increase from the current price of $35.20. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Pacs Group Inc.'s business model?
PACS Group Inc. generates revenue by managing a diverse portfolio of over 300 independently operated healthcare facilities that provide skilled nursing, assisted living, and independent living services. The company enhances its income through offering comprehensive support services, including technology solutions and training programs, to its affiliated providers, thereby creating a robust ecosystem that ensures consistent care and operational efficiency.
What is the highest forecasted price for PACS Pacs Group Inc.?
The highest price target for PACS is $52.00 from Ben Hendrix at RBC Capital, which represents a 47.7% increase from the current price of $35.20.
What is the lowest forecasted price for PACS Pacs Group Inc.?
The lowest price target for PACS is $42.00 from Michael Wiederhorn at Oppenheimer, which represents a 19.3% increase from the current price of $35.20.
What is the overall PACS consensus from analysts for Pacs Group Inc.?
The overall analyst consensus for PACS is bullish. Out of 11 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $44.00.
How accurate are PACS stock price projections?
Stock price projections, including those for Pacs Group Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 6:42 PM UTC